WPG Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

WPG Advisers’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$566	Hold	18	–	–	﹤0.01%	1425
2026 Q1	$446	Hold	18	–	–	﹤0.01%	1373
2025 Q4	$420	Hold	18	–	–	﹤0.01%	1402
2025 Q3	$355	Hold	18	–	–	﹤0.01%	1397
2025 Q2	$391	Hold	18	–	–	﹤0.01%	1371
2025 Q1	$437	Hold	18	–	–	﹤0.01%	1362
2024 Q4	$376	Buy	+18	New	+$387	﹤0.01%	1385

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WPG Advisers's CPRX Position: Q2 2026 in Review

WPG Advisers held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 18 shares worth $566. The position accounts for ﹤0.01% of the portfolio, ranked #1425.

WPG Advisers first reported a position in CPRX in Q4 2024 and has held it in 7 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

WPG Advisers held 18 shares of Catalyst Pharmaceutical worth $566 as of Q2 2026.
WPG Advisers left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
Catalyst Pharmaceutical made up ﹤0.01% of WPG Advisers's portfolio in Q2 2026, its #1425 holding.
WPG Advisers first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 7 quarters since.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.